# Rezvilutamide for High-Risk Prostate Cancer After Surgery

> **NCT07444983** · NA · NOT_YET_RECRUITING · sponsor: **Fujian Medical University Union Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)

## Interventions

- **DRUG:** Rezvilutamide and Leuprorelin

## Key facts

- **NCT ID:** NCT07444983
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-11
- **Primary completion:** 2027-02-11
- **Final completion:** 2029-07-11
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07444983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07444983, "Rezvilutamide for High-Risk Prostate Cancer After Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07444983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*